ArticleJournal of cardiovascular translational research2025
Senescence-related Genes as Prognostic Markers for STEMI Patients: LASSO Regression-Based Bioinformatics and External Validation.
Article in Journal of cardiovascular translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The prognostic value of differentially expressed senescence-related genes(DESRGs) in ST-segment elevation myocardial infarction(STEMI) patients is unclear. We used GEO2R to identify DESRGs from GSE60993 and performed functional enrichment analysis. We built an optimal prognostic model with LASSO penalized Cox regression via GSE49925. We evaluated the model with survival analysis, ROC curve, decision curve analysis, nomogram, and external validation with plasma samples. We created a prognostic signature with three dysregulated DESRGs (CDC25B, FKBP5, and ECHDC3) and two clinical variables (serum creatinine, Gensini score). The signature stratified patients into low- and high-risk groups and showed strong predictive performance within two years. The external validation confirmed the survival difference between the groups. We identified three DESRGs that were differentially expressed and prognostic in STEMI patients. The model incorporating three DESRGs showed promising prediction and utility for stratifying patients and estimating survival risk in STEMI patients.
Indexed as
Identifiers
39786668What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.